Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Conferences | Events

Quotient announces agreement with Phico Therapeutics and first application of RapidFACT for nasal delivery

Quotient_ClinicalQuotient Clinical, a business unit of Quotient Bioresearch (Quotient), today announced an agreement with UK-based biotech, Phico Therapeutics (Phico). Quotient will undertake a RapidFACTTM program to optimise nasal delivery of Phico's SASPjectTM PT1.2, an antibiotic protein technology that offers a new approach for the treatment of serious life-threatening bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA). 

RapidFACT will be used to screen alternative formulations designed to enhance nasal delivery, retention, and efficacy of SASPject in intranasal S. aureus carriers. RapidFACT exploits Quotient's Translational PharmaceuticsTM platform to enable the rapid clinical screening and optimisation of drug products. Compared to conventional development processes, RapidFACT shortens project timelines and reduces active ingredient consumption by up to ~90 per cent, all of which combine to deliver significant cost savings. This is the first time that RapidFACT has been used to optimise nasal delivery, and is also the first time that it has employed a pharmacodynamics endpoint to guide formulation development. 

Mark Egerton, MD of Quotient Clinical, commented:  "We are delighted to be working with Phico on the SASPject technology. RapidFACT has been used on a wide variety of oral products and this is the first example of its use on a nasal product, demonstrating RapidFACT's broad utility. It is also pleasing that we have been able to integrate Quotient's specialist microbiological services into this project. We are looking forward to delivering an optimised drug product for the next stages of development, and helping Phico to accelerate its novel approach into patient studies."

Dr Heather Fairhead, CEO of Phico commented: "This will be the second trial we have conducted with Quotient Clinical and we are very pleased to be working with the Quotient team again.  We expect to benefit once more from their professional and helpful approach and the use of RapidFACT for this application is an added bonus which should save Phico time and money at this critical stage of clinical development with SASPject PT1.2."

For more information on Quotient Clinical, please call UK +44 (0)115 974 9000, USA - 1-800-769-3518, email clinical@quotientbioresearch.com or visit www.quotientbioresearch.com/clinical.


If you have not logged into the website then please enter your details below.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

Today's Picks

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners